8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  August 2, 2011
SYNUTRA INTERNATIONAL, INC.
(Exact Name of Registrantas Specified in Charter)
Delaware	001-33397	13-4306188
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2275 Research Blvd., Suite 500, Rockville, MD		20850
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s telephone number, including area code:  (301) 840-3888
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 2, 2011, Synutra International, Inc. (the “Company”) issued a press release commenting on its financial results for its fiscal quarter ended June 30, 2011.  A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits

(d)           Exhibits

99.1           Text of press release issued by Synutra International, Inc. dated August 2, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

		SYNUTRA INTERNATIONAL, INC.(Registrant)
Date:	August 2, 2011	By:	/s/ Weiguo Zhang
			Name:	Weiguo Zhang
			Title:	President

EXHIBIT INDEX

Exhibit No.	Description
99.1	Text of press release issued by Synutra International, Inc. dated August 2, 2011

EX-99.1

EXHIBIT 99.1

FOR IMMEDIATE RELEASE:

Synutra Comments on its First Quarter of Fiscal 2012

Earnings Release Scheduled for August 9, 2011

Qingdao, China and Rockville, Md. – August 2, 2011 – Synutra International, Inc. (NASDAQ: SYUT), a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today commented on its financial performance for the first quarter of fiscal 2012, which ended June 30, 2011.

Mr. Donghao Yang, Chief Financial Officer of Synutra, commented, “As of this point, we expect to report next week a net loss for the first quarter of 2012, although we continue to get closer to reaching profitability. There have also been notable improvements in the first quarter, including a continued recovery in our branded infant formula sales and an increase in market share to 5.3% in June.”

Yang continued, “Two key events should be pointed out ahead of our conference call next week.  First, we decided not to enter into industrial milk powder sales in the first quarter.  We did not need the short term financing these sales typically produce, and while we may pursue such sales in the future, we decided against the low margin revenue this quarter.  Second, net sales from our branded powdered formula segment were approximately $40.2 million in the first quarter.  These net sales were impacted by the delay of whey powder delivery from our European supplier, which caused us to recognize approximately $16.6 million of branded infant formula sales in the month of July instead of in the month of June.  We do not view this as a substantive issue, since the orders are intact and shipped in July, but the timing did undermine top line results for the first quarter.  We look forward to discussing our financial results in more detail next week, once we have completed our accounting review and have published results.”

Synutra plans to release financial results for the first quarter of fiscal 2012 on Tuesday, August 9, 2011, after the market closes.  The Company will hold a conference call on Wednesday, August 10, 2011 at 8:00 am Eastern Time to discuss the financial results.  Listeners may access the call by dialing the following numbers:

United States Toll Free:	+1 (866) 405-2350
International:	+1 (718) 354-1231
Conference ID:	83225375

The replay will be accessible through August 18, 2011 by dialing the following numbers:

United States Toll Free:	+1 (866) 214-5335
International:	+1 (718) 354-1232
Conference ID:	83225375

A webcast of the conference call will be available through the Company’s IR website at www.synutra.com.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering 30 provinces and provincial-level municipalities in China. As of March 31, 2011, this network comprised over 580 independent distributors and over 1,000 independent sub-distributors who sell Synutra products in over 71,000 retail outlets.

FOR FURTHER INFORMATION:

Synutra International, Inc.

Investor Relations Department

ir@synutra.com or 301-840-3881